PE20071042A1 - Producto farmaceutico que comprende temsirolimus y malato de sunitinib - Google Patents

Producto farmaceutico que comprende temsirolimus y malato de sunitinib

Info

Publication number
PE20071042A1
PE20071042A1 PE2006001343A PE2006001343A PE20071042A1 PE 20071042 A1 PE20071042 A1 PE 20071042A1 PE 2006001343 A PE2006001343 A PE 2006001343A PE 2006001343 A PE2006001343 A PE 2006001343A PE 20071042 A1 PE20071042 A1 PE 20071042A1
Authority
PE
Peru
Prior art keywords
sunitinib malate
temsirolimus
pharmaceutical product
product including
inhibitor
Prior art date
Application number
PE2006001343A
Other languages
English (en)
Inventor
Laurence Moore
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37882361&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20071042A1 publication Critical patent/PE20071042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA ENZIMA BLANCO DE RAPAMICINA EN MAMIFEROS (mTOR) QUE ES TEMSIROLIMUS; Y B) MALATO DE SUNITINIB, ADMINISTRADOS EN UNA CANTIDAD SUBTERAPEUTICAMENTE EFECTIVA. DONDE LA COMBINACION COMPRENDE ADEMAS OTRO COMPONENTE ACTIVO SELECCIONADO DE AGENTES ALQUILANTES ANTINEOPLASICOS TAL COMO CICLOFOSFAMIDA, CLORAMBUCIL, CISPLATINO, ENTRE OTROS; AGENTES ANTIMETABOLITO ANTINEOPLASICOS TAL COMO CITARABINA, METOTREXATO, GEMCITABINA, ENTRE OTROS; INMUNOMODULADORES BIOQUIMICOS TAL COMO LEUCOVORINA O LEVOFOLINATO; IMATINIB; INHIBIDORES DE EGFR, INHIBIDOR MULTIQUINASA O UN INTERFERON. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE CARCINOMA DE CELULAS RENALES, CANCER DE MAMA, CANCER DE COLON, LEUCEMIA
PE2006001343A 2005-11-04 2006-11-02 Producto farmaceutico que comprende temsirolimus y malato de sunitinib PE20071042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73356405P 2005-11-04 2005-11-04

Publications (1)

Publication Number Publication Date
PE20071042A1 true PE20071042A1 (es) 2007-10-12

Family

ID=37882361

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001343A PE20071042A1 (es) 2005-11-04 2006-11-02 Producto farmaceutico que comprende temsirolimus y malato de sunitinib

Country Status (5)

Country Link
US (1) US20070105887A1 (es)
AR (1) AR058505A1 (es)
PE (1) PE20071042A1 (es)
TW (1) TW200803842A (es)
WO (1) WO2007056117A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008379B1 (ru) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
WO2006084058A2 (en) * 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP1962839A4 (en) * 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20080161335A1 (en) 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
US20100087499A1 (en) * 2007-01-30 2010-04-08 Schering Corporation Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009065232A1 (en) * 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
ES2958968T3 (es) 2008-06-17 2024-02-16 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
SI2326329T1 (sl) 2008-08-04 2017-06-30 Wyeth Llc Antineoplastične kombinacije 4-anilino-3-cianakinolinov in kapecitabina
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
MX2012013255A (es) 2010-05-14 2013-02-27 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
US20120082647A1 (en) * 2010-10-01 2012-04-05 Baker Darren P Interferon-beta for use as monotherapy or in combination with other cancer therapies
KR20140123558A (ko) 2012-02-02 2014-10-22 악셀레론 파마 인코포레이티드 Alk1 길항제 및 신세포 암종 치료에서의 그의 용도
MX365392B (es) * 2012-03-06 2019-05-31 Univ Illinois Composición de combinación de pac-1 y doxorrubicina.
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
EP3066101B1 (en) * 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
PE20171042A1 (es) 2014-10-27 2017-07-19 Tensha Therapeutics Inc Inhibidores del bromodominio
CN105434435B (zh) * 2015-12-07 2018-07-17 西安交通大学 一种具有协同抗肿瘤功效的药物组合物及其应用
AU2018388439B2 (en) * 2017-12-20 2021-05-20 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2005049021A1 (en) * 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
KR20070119745A (ko) * 2005-05-12 2007-12-20 화이자 인코포레이티드 수니티닙 말레이트를 사용하는 항암 병행 요법

Also Published As

Publication number Publication date
TW200803842A (en) 2008-01-16
US20070105887A1 (en) 2007-05-10
WO2007056117A1 (en) 2007-05-18
AR058505A1 (es) 2008-02-06

Similar Documents

Publication Publication Date Title
PE20071042A1 (es) Producto farmaceutico que comprende temsirolimus y malato de sunitinib
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CR9875A (es) Inhibidores de dipeptidilo peptidasa para tratar diabetes
CO6270257A2 (es) Derivados de piridazinona
GEP20125564B (en) Pyrimidine derivatives as kinase inhibitors
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
ECSP088598A (es) Derivados de piridazinona
EA201200578A1 (ru) Сульфоксидные производные для лечения опухолей
GT200500225A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
ECSP10010361A (es) Derivados de piridazinona
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
NZ622505A (en) Therapeutic compounds and compositions
WO2010025872A3 (en) Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
TNSN08078A1 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
CR11065A (es) Administracion semanal de inhibidores de peptidasa de dipeptidilo
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака

Legal Events

Date Code Title Description
FA Abandonment or withdrawal